Anis Hamid, MBBS, discusses the progression of therapy for metastatic prostate cancer.
Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the progression of therapy for metastatic prostate cancer.
The standard of care for patients with metastatic prostate cancer was androgen deprivation therapy, explains Hamid. The randomized phase III CHAARTED trial, which reported out about 6 years ago, showed that the addition of docetaxel given upon diagnosis significantly improves the survival of patients with newly diagnosed prostate cancer, says Hamid.
After the CHAARTED trial and other related trials, docetaxel became the standard treatment for patients with metastatic prostate cancer. Since then, a number of different treatments were introduced in a similar setting, including the hormonal therapies abiraterone acetate (Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada), concludes Hamid.